SAN FRANCISCO – New clinical data from Gilead Sciences Inc. and Bristol-Myers Squibb Co., presented at the American Association for the Study of Liver Diseases Annual Meeting added support to the drugmakers' cases for the efficacy of therapeutic combinations capable of battling HCV, especially among those patient with hard-to-treat cases.